Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review - PubMed (original) (raw)

Review

Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review

Enakshi Sivasudhan et al. Cells. 2022.

Abstract

With 296 million cases estimated worldwide, chronic hepatitis B virus (HBV) infection is the most common risk factor for hepatocellular carcinoma (HCC). HBV-encoded oncogene X protein (HBx), a key multifunctional regulatory protein, drives viral replication and interferes with several cellular signalling pathways that drive virus-associated hepatocarcinogenesis. This review article provides a comprehensive overview of the role of HBx in modulating the various hallmarks of HCC by supporting tumour initiation, progression, invasion and metastasis. Understanding HBx-mediated dimensions of complexity in driving liver malignancies could provide the key to unlocking novel and repurposed combinatorial therapies to combat HCC.

Keywords: HBx protein; cancer hallmarks; hepatitis B virus; hepatocellular carcinoma; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Hallmarks of hepatocellular carcinoma modulated by hepatitis B virus X protein (HBx). Numerous liver tumorigenesis-driving hallmarks influence the downstream cellular mechanisms by sustaining proliferative signalling, eluding growth suppressors, evading immune destruction, facilitating replicative immortality, aiding in tumour-promoting inflammation, triggering invasion and metastasis, prompting angiogenesis, inducing genome instability, preventing cell apoptosis, and deregulating cellular energetics.

References

1. World Health Organization Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. 2021. [(accessed on 29 December 2021)]. Available online: https://www.who.int/publications/i/item/9789240027077.
1. Wong V.W.-S., Janssen H.L.A. Can we use hcc risk scores to individualize surveillance in chronic hepatitis b infection? J. Hepatol. 2015;63:722–732. doi: 10.1016/j.jhep.2015.05.019. - DOI - PubMed
1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
1. Kgatle M. Advances in Treatment of Hepatitis C and B. IntechOpen; London, UK: 2017. Recent advancement in hepatitis b virus, epigenetics alterations and related complications.
1. Seeger C., Mason W.S. Hepatitis b virus biology. Microbiol. Mol. Biol. Rev. MMBR. 2000;64:51–68. doi: 10.1128/MMBR.64.1.51-68.2000. - DOI - PMC - PubMed

Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review - PubMed (original) (raw)